Aclacinomycin A HCl

SKU: orb1992962

Description

Aclarubicin hydrochloride is an anthracycline antibiotic that inhibits topoisomerase I/II and the 20S proteasome, disrupting DNA processes and generating ROS. It is used in research for studying relapsed leukemia and advanced lymphoma, with applications in both in vitro and in vivo models of oncology and cancer pharmacology.

Research Area

Cell Biology, Protein Biochemistry

Key Properties

• CAS Number: 75443-99-1
• MW: 848.3
• Purity: >90%
• Formula: C₄₂H₅₃NO₁₅ HCl
• SMILES: C(OC)(=O)[C@@H]1C2=C([C@@H](O[C@H]3C[C@H](N(C)C)[C@H](O[C@H]4C[C@H](O)[C@H](O[C@@H]5O[C@@H](C)C(=O)CC5)[C@H](C)O4)[C@H](C)O3)C[C@@]1(CC)O)C(O)=C6C(=C2)C(=O)C=7C(C6=O)=C(O)C=CC7.Cl
• Target: Proteasome
• Solubility: Soluble in DMSO (up to 30 mg/ml).

Bioactivity

• In Vivo:
  Method: P-388 leukemia cells were transplanted into DBA/2 and CDF1 (BALB/c × DBA/2) mice. Starting 3 hours after transplantation, mice received daily intraperitoneal injections of Aclacinomycin A hydrochloride for 10 consecutive days at doses of 0.75, 1.5, 3, and 6 mg/kg. Result: Aclacinomycin A hydrochloride significantly inhibited tumor growth in a dose-dependent manner.
• In Vitro:
  Method: A cell viability assay was performed using V79 and irs-2 cell lines. Cells were treated with varying concentrations of Aclacinomycin A hydrochloride at 0, 0.006, 0.12, 1.2, and 2.4 μM for 3 hours. The effect on the catalytic activity of topoisomerase II (topo II) was evaluated. Result: Aclacinomycin A hydrochloride significantly inhibited topo II catalytic activity in a dose-dependent manner. Compared to the untreated group, all treated groups showed a statistically significant decrease in topo II activity, indicating that the drug effectively interferes with topo II function and subsequently affects cell viability.
• Animal Research:
  Animal Model: DBA/2, CDF1 (BALB/c×DBA/2) mice with Leukemia P-388. Dosage: 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. Administration: Intraperitoneal administration daily for 10 days starting 3 hr after transplantation. Result: Inhibited tumor growth .

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Aclarubicin hydrochloride

Compound Identifiers

PubChem CID

153751